Oncocyte Corp
For the period ended Dec 31, 2023. Filed Apr 16, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 16, 2024
IMDX$2.47-1.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
| Years Ended | ||||
|---|---|---|---|---|
| December 31, | ||||
| 2023 · 2022 | ||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||
| Net loss | $(27,781) | $(72,902) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Depreciation and amortization expense | 1,592 | 1,528 | ||
| Amortization of intangible assets | 88 | 3,692 | ||
| Stock-based compensation | 2,760 | 10,042 | ||
| Equity compensation for bonus awards and consulting services | 127 | - | ||
| Realized and unrealized loss on marketable equity securities, net | 61 | 471 | ||
| Amortization of debt issuance costs | - | 12 | ||
| Change in fair value of contingent consideration | (5,762) | (31,019) | ||
| Impairment losses | 6,757 | - | ||
| Goodwill impairment | - | 18,684 | ||
| Loss on disposal of discontinued operations | 1,521 | - | ||
| Loss on disposal and held for sale assets | 1,283 | - | ||
| Impairment loss from held for sale assets of discontinued operations (Note 13) | - | 25,866 | ||
| Changes in operating assets and liabilities: | ||||
| Accounts receivable | 109 | (575) | ||
| Prepaid expenses and other assets | 784 | (231) | ||
| Accounts payable and accrued liabilities | (4,757) | 297 | ||
| Accrued severance and liabilities from Chronix Biomedical acquisition | - | (1,317) | ||
| Lease assets and liabilities | (107) | (116) | ||
| Net cash used in operating activities | (23,325) | (45,568) | ||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||
| Proceeds from sale of marketable equity securities | 367 | - | ||
| Proceeds from sale of equipment | 354 | - | ||
| Construction in progress and purchases of furniture and equipment | (281) | (4,340) | ||
| Cash sold in discontinued operations (Note 13) | (1,372) | - | ||
| Net cash used in investing activities | (932) | (4,340) | ||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||
| Proceeds from sale of common shares | 13,848 | 32,812 | ||
| Financing costs to issue common shares | (427) | (389) | ||
| Proceeds from sale of redeemable convertible Series A preferred shares | - | 4,875 | ||
| Redemption of redeemable convertible Series A preferred shares | (1,118) | - | ||
| Financing costs to issue redeemable convertible Series A preferred shares | - | (93) | ||
| Proceeds from sale of common shares under at-the-market transactions | - | 31 | ||
| Financing costs for at-the-market sales | - | (1) | ||
| Repayment of bank loan | - | (1,325) | ||
| Repayment of financing lease obligations | (117) | (104) | ||
| Net cash provided by financing activities | 12,186 | 35,806 | ||
| NET CHANGE IN CASH, CASH EQUIVALENTS (INCLUDES DISCONTINUED OPERATIONS) AND RESTRICTED CASH | (12,071) | (14,102) | ||
| CASH, CASH EQUIVALENTS (INCLUDES DISCONTINUED OPERATIONS) AND RESTRICTED CASH, BEGINNING | 23,203 | 37,305 | ||
| CASH, CASH EQUIVALENTS (INCLUDES DISCONTINUED OPERATIONS) AND RESTRICTED CASH, ENDING | $11,132 | $23,203 | ||
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION | ||||
| Cash paid for interest | $ | - | $24 | |
| Cash paid for income taxes | $ | - | $ | - |
| SUPPLEMENTAL SCHEDULE OF NONCASH INVESTING AND FINANCING ACTIVITIES | ||||
| Construction in progress, machinery and equipment purchases included in accounts payable and accrued liabilities | $ | - | $323 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.